Key result
Anticoagulation in malignant superior vena cava syndrome was associated with 0% thromboembolic complications (0/15) versus 50% (5/10) without anticoagulation, though 2 fatal hemorrhages occurred.
Why the study?
Does anticoagulation prevent thromboembolic complications in patients with malignant superior vena cava syndrome?
Cohort (n=25)
Does anticoagulation prevent thromboembolic complications in patients with malignant superior vena cava syndrome?
Anticoagulation may prevent thromboembolic complications in malignant superior vena cava syndrome, but it carries a significant risk of fatal intracranial hemorrhage, underscoring the need for randomized trials.
Answers are grounded in this paper and cite their sources.
Anticoagulation was associated with fewer thromboembolic events yet fatal bleeds in malignant SVC syndrome; leaves open net benefit pending randomized trials.
In patients with superior vena caval obstruction resulting from malignancy, the importance of vena caval thrombosis and the role of anticoagulation are incompletely understood. The authors discuss this aspect of the management of 25 patients with malignant superior vena cava syndrome. Ten patients were retrospectively reviewed after having been clinically diagnosed without venography, and treated without anticoagulation. Five thromboembolic complications occurred, two of which proved fatal. Fifteen patients were prospectively evaluated by angiography and then treated with anticoagulants. Angiographic evidence of intraluminal subclavian vein or superior vena caval thrombosis was found in five of these patients, and no thromboembolic complications occurred. Of the 20 patients ultimately anticoagulated, two fatal intracranial hemorrhages developed. The authors suggest the need for randomized prospective trials if the role of venography and anticoagulation in this syndrome is to be determined.
No takes yet. Share an insight, caveat, or question.
Adelstein et al. (1988) conducted a cohort in Malignant superior vena cava syndrome (n=25). Anticoagulation vs. No anticoagulation was evaluated on Thromboembolic complications. Anticoagulation in malignant superior vena cava syndrome was associated with 0% thromboembolic complications (0/15) versus 50% (5/10) without anticoagulation, though 2 fatal hemorrhages occurred.
Synapse has enriched 10 related papers. Consider them for comparative context: